Ocular medicines in children: the regulatory situation related to clinical research

BMC Pediatrics

Maurizio Bonati¹  Antonio Clavenna¹  Filomena Fortinguerra¹ 

[1] Laboratory for Mother and Child Health, Department of Public Health, Mario Negri Institute for Pharmacological Research, Milan, Italy

关键词: paediatrics;    drug therapy;    eye diseases;    ocular medicines;    review;   

Others  :  1178939
DOI  :  10.1186/1471-2431-12-8

 received in 2011-05-09, accepted in 2012-01-20,  发布年份 2012

【 摘 要 】

Background

Many ocular medications are prescribed for paediatric patients, but the evidence for their rational use is very scant. This study was planned to compare the availability and the licensing status of ocular medications marketed in Italy, the United Kingdom (UK), and the United States of America (USA) related to the amount of published and un-published RCTs testing these drugs in the paediatric population.

Methods

A quantitative analysis was performed to evaluate the number of ocular medications with a paediatric license in Italy, the UK, and the USA. A literature search was also performed in MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials for randomized controlled trials (RCTs) on ophthalmic pharmacological therapy in children aged < 18 years, published up to December 2010. A search in the international clinical trial registries, the list of paediatric investigation plans (PIPs) approved by European Medicines Agency (EMA), and the table of medicines with new paediatric information approved by Food and Drug Administration (FDA) was also performed.

Results

In all, of 197 drugs identified, 68 (35%) single drugs are licensed for paediatric use at least in one considered country, while 23 (12%) were marketed in all three countries. More specifically, in Italy 43 single drugs (48% of those marketed) had a paediatric license, while 39 (64%) did in the UK and 22 (54%) did in the USA. Only 13 drugs were marketed with a paediatric license in all countries.

The percentage of drugs licensed for paediatric use and for which at least one RCT had been performed ranged between 51% in Italy and 55% in the USA. No published RCTs were found for 11 (48%) drugs licensed for paediatric use in all three countries. In all, 74 (35%) of the retrieved RCTs involved mydriatic/cycloplegic medications.

A total of 62 RCTs (56% completed) on 46 drugs were found in the international clinical trial registries. Cyclosporin and bevacizumab were being studied in many ongoing trials. Twenty-six drugs had new paediatric information approved by FDA based on new paediatric clinical trials, while only 4 PIPs were approved by EMA.

Conclusions

There is a pressing need for further research and clinical development in the pediatric ophthalmic area, where effective up-to-date treatments, and additional research and education on use in children, remain priorities.

【 授权许可】

   
2012 Fortinguerra et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Wallace DK, Steinkuller PG: Ocular Medications in Children. Clinical Pediatrics 1998, 37:645-652.
• [2]Cumberland PM, Pathai S, Rahi JS, for the Millennium Cohort Study Child Health Group: Prevalence of Eye Disease in Early Childhood and Associated Factors. Findings from the Millennium Cohort Study. Ophthalmology 2010, 117:2184-2190.
• [3]Roarty JD: Ophthalmologic drugs in infants and children. In Neonatal and Pediatric Pharmacology. 3rd edition. Edited by Yaffe SJ, Aranda JV, Lippincott Williams & Wilkins. Philadelphia, PA; 2005:340-348.
• [4]Chung I, Buhr V: Topical ophthalmic drugs and the pediatric patient. Optometry 2000, 71:511-518.
• [5]Coulter RA: Pediatric use of topical ophthalmic drugs. Optometry 2004, 75:419-429.
• [6]Levy Y, Zadok D: Systemic side effects of ophthalmic drops. Clin Pediatr (Phila) 2004, 43:99-101.
• [7]Metry DW, Hebert AA: Topical therapies and medications in the paediatric patient. Pediatr Clin North Am 2000, 47:867-876.
• [8]Martinez SV, Junceda MC: Systemic adverse reactions to topical ocular medications in children: A call for attention. Acta Pediátrica Española 2005, 63:121-122.
• [9]Coppens G, Stalmans I, Zeyen T, Casteels I: The safety and efficacy of glaucoma medication in the pediatric population. J Pediatr Ophthalmol Strabismus 2009, 46:12-18.
• [10]World Health Organization (WHO): Collaborating Centre for Drug Statistics Methodology. [http://www.whocc.no/atcddd/] webciteWorld Health Organization (WHO); Accessed on: 5/5/2011
• [11]Elsevier: Banche dati dell'Informatore Farmaceutico. [http://www.codifa.it] webcite Elsevier Accessed on: 5/5/2011
• [12]British National Formulary 2010-2011: British National Formulary for Children. [http://bnfc.org/bnfc/index.htm] webciteBritish National Formulary 2010-2011; Accessed on: 5/5/2011
• [13]PDR Network: Physicians' Desk Reference® (PDR®). [http://www.pdr.net/Default.aspx] webcite PDR Network Accessed on: 5/5/2011
• [14]World Health Organization (WHO): WHO The International Clinical Trials Registry Platform. ICTRP. [http://www.who.int/trialsearch] webciteWorld Health Organization (WHO); Accessed on: 5/5/2011
• [15]US National Institutes of Health: ClinicalTrials.gov registry. [http://clinicaltrials.gov/ct2/search] webciteUS National Institutes of Health; Accessed on: 5/5/2011
• [16]Current Controlled Trials Ltd: International Standard Randomised Controlled Trial Number Register. ISRCTN. [http://www.controlled-trials.com/isrctn/] webciteCurrent Controlled Trials Ltd; Accessed on: 5/5/2011
• [17]European Medicines Agency (EMA): Opinions and Decisions on Paediatric Investigation Plans (PIPs). [http:/ / www.ema.europa.eu/ ema/ index.jsp?curl=pages/ medicines/ landing/ pip_search.jsp&murl=menus/ medicines/ medicines.jsp&mid=WC0b01ac058001d12 9] webciteEuropean Medicines Agency (EMA); Accessed on: 5/5/2011
• [18]European Medicines Agency (EMA): List of active substances for which data has been submitted in accordance with Article 45 of the Paediatric Regulation. [http://www.hma.eu/99.html] webcite Accessed on: 5/5/2011
• [19]Food and Drug Administration (FDA): Table of Medicines with New Pediatric Information. [http:/ / www.fda.gov/ downloads/ ScienceResearch/ SpecialTopics/ PediatricTherapeuticsResearc h/ UCM163159.pdf] webciteFood and Drug Administration (FDA); Accessed on: 5/5/2011
• [20]European Medicines Agency (EMA): Revised priority list for studies into off-patent paediatric medicinal products for the Fifth Call 2010 of the 7th Framework Programme of the European Commission. [http:/ / www.ema.europa.eu/ docs/ en_GB/ document_library/ Other/ 2009/ 10/ WC500004017.pdf] webciteEuropean Medicines Agency (EMA); Accessed on: 5/5/2011
• [21]University of Texas, School of Nursing, Family Nurse Practitioner Program: Guidelines for the treatment and management of acute bacterial conjunctivitis in children and adults (2005). [http://www.guidelines.gov/content.aspx?id=7353] webciteUniversity of Texas, School of Nursing Austin (TX); Accessed on: 5/5/2011
• [22]Cincinnati Children's Hospital Medical Center: Best evidence statement (BESt). Treatment of amblyopia in children. [http://www.guideline.gov/content.aspx?id=14288] webciteCincinnati Children's Hospital Medical Center; 2007. Accessed on: 5/5/2011
• [23]The Royal College of Ophthalmologists. Paediatric Sub-Committee: Guidelines for the Management of Amblyopia. [http://www.rcophth.ac.uk/page.asp?section=493&search=] webciteThe Royal College of Ophthalmologists; 2006. Accessed on: 5/5/2011
• [24]Taylor RH: Guidelines for the Management of Strabismus in Childhood. [http:/ / rcophth-website.www.premierithostin g.com/ docs/ publications/ paed-patient-information/ Strabismus.pdf] webcite June 2007 Author Review Date 2009. The Royal College of Ophthalmologists Accessed on: 5/5/2011
• [25]Moore W, Nischal KK: Pharmacologic management of glaucoma in childhood. Paediatr Drugs 2007, 9:71-79.
• [26]Royal College of Paediatrics and Child Health: Guideline for the Screening and Treatment of Retinopathy of Prematurity. [http:/ / www.rcophth.ac.uk/ page.asp?section=451§ionTitle=C linical+Guidelines] webcite 2008. Accessed on: 5/5/2011
• [27]Zin A, Florêncio T, Fortes Filho JB, Nakanami CR, Gianini N, Graziano RM, et al.: Brazilian guidelines proposal for screening and treatment of retinopathy of prematurity (ROP). Arq Bras Oftalmol 2007, 70:875-883.
• [28]Canadian Paediatric Society, Infectious Diseases and Immunization Committee: Recommendations for prevention of neonatal ophthalmia. Can Med Assoc J 2002, 129:554-555.
• [29]Gray C: Systemic toxicity with topical ophthalmic medications in Children. Paed Perinat Drug Ther 2006, 7:23-29.
• [30]Abraham J: Making regulation responsive to commercial interests: streamlining drug industry watchdogs. BMJ 2002, 325:1164-1169.
• [31]Nonobe NI, Kachi S, Kondo M, Takai Y, Takemoto K, Nakayama A, et al.: Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab. Retina 2009, 29:579-585.
• [32]Sassa Y, Hata Y: Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor. Clin Ophthalmol 2010, 4:275-283.
• [33]Kusaka S, Shima C, Wada K, Arahori H, Shimojyo H, Sato T, et al.: Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 2008, 92:1450-1455.
• [34]Lalwani GA, Berrocal AM, Murray TG, Buch M, Cardone S, et al.: Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008, 28(Suppl 3):S13-18.
• [35]Lin KL, Hirose T, Kroll AJ, Lou PL, Ryan EA: Prospects for Treatment of Pediatric Vitreoretinal Diseases with Vascular Endothelial Growth Factor Inhibition. Seminars in Ophthalmology 2009, 24:70-76.
• [36]Mantagos IS, Vanderveen DK, Smith LE: Emerging Treatments for Retinopathy of Prematurity. Seminars in Ophthalmology 2009, 24:82-86.
• [37]Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RV: Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008, 28(Suppl 3):S19-25.
• [38]Macrae D: Conducting clinical trials in pediatrics. Crit Care Med 2009, 37(Suppl 1):S136-139.
• [39]Labetoulle M, Frau E, Le Jeunne C: Systemic adverse effects of topical ocular treatments. Presse Med 2005, 34:589-595.
• [40]Sheldrick JH, Wilson AD, Vernon SA, Sheldrick CM: Management of ophthalmic disease in general practice. Br J Gen Pract 1993, 43:459-462.
• [41]Hoppu K: Paediatric clinical pharmacology at the beginning of a new era. Eur J Clin Pharmacol 2008, 64:201-205.
• [42]Jefferys DB, Jones KH: Emea and the new pharmaceutical procedures for Europe. Eur J Clin Pharmacol 1995, 47:471-476.
• [43]Pandolfini C, Bonati M: European paediatric research and children's therapeutic needs. Acta Pardiatrica 2008, 97:1232-1237.
• [44]Choonara I: Regulation of drugs for children in Europe. BMJ 2007, 335:1221-1222.
• [45]Hoppu K: Can we get the necessary clinical trials in children and avoid the unnecessary ones? Eur J Clin Pharmacol 2009, 65:747-748.
• [46]Bonati M, Pandolfini : Is it time for a European formulary of paediatric medicines? Arch of Dis Child 2004, 89:890-891.